Advertisement

Collaboration › Details
Moderna–Wells Fargo: investor conference, 202109 supply service Moderna presents at Wells Fargo 2021 Virtual Healthcare Conference
![]() |
Period | 2021-09-10 |
![]() |
Partner, 1st | Moderna Inc. (Nasdaq: MRNA) |
Group | Moderna (Group) | |
Partner, 2nd | Wells Fargo Securities LLC | |
Group | Wells Fargo (Group) | |
![]() |
Product | Wells Fargo Healthcare Conference 2021 DIGITAL |
Product 2 | mRNA technology | |
Moderna, Inc.. (9/2/21). "Press Release: Moderna to Present at Upcoming Investor Conferences in September 2021". Cambridge, MA.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:
> Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:00 a.m. ET
> Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:45 a.m. ET
A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.
About Moderna
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 23 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
Record changed: 2021-09-12 |
Advertisement

More documents for Moderna (Group)
- [1] Moderna, Inc.. (4/27/22). "Press Release: Arpa Garay Joins Moderna as Chief Commercial Officer". Cambridge, MA....
- [2] Metagenomi Inc.. (11/2/21). "Press Release: Metagenomi and Moderna Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics". Emeryville, CA & Cambirdge, MA....
- [3] Moderna, Inc.. (9/3/21). "Press Release: Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster". Cambridge, MA....
- [4] Moderna, Inc.. (9/2/21). "Press Release: Moderna to Present at Upcoming Investor Conferences in September 2021". Cambridge, MA....
- [5] Moderna, Inc.. (6/28/21). "Press Release: Kate Cronin to Join Moderna as Chief Brand Officer on July 12". Cambridge, MA....
- [6] Moderna, Inc.. (6/1/21). "Press Release: Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands". Albstadt....
- [7] Moderna, Inc.. (5/19/21). "Press Release: Moderna to Establish an International Business Services Hub in Warsaw, Poland. Entity Complements Six Commercial Entities in Europe". Cambridge, MA....
- [8] DNA Script. (4/27/21). "Press Release: DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA". Paris & Cambridge, MA....
- [9] Flagship Pioneering. (1/12/21). "Press Release: Flagship Pioneering Launches Pioneering Medicines". Cambridge, MA....
- [10] Moderna, Inc.. (1/6/21). "Press Release: European Commission Authorizes COVID-19 Vaccine Moderna in Europe". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top